Click on image to view larger version.

Figure 3 (A) Subsequent survival in patients with idiopathic pulmonary arterial hypertension (IPAH) stratified by functional class after 1 year epoprostenal treatment 1: p < 0.001 for functional class III vs. functional class IV and for functional class III vs. functional class I and functional class II (30). (B) Survival in patients with IPAH treated with intravenous epoprostenol according to New York Heart Association (NYHA) functional class. After three months of treatment with epoprostenol, survival rates for patients reclassified in NYHA functional class I or II (solid line) were 100%, 93%, and 88% at one, two, and three years, respectively, as compared with 77%, 46%, and 33% for patients persisting in NYHA functional class III or IV (dashed line) (p < 0.001 by the Cox-Mantel log-rank test) (32).